April 4, 2018 07:00 AM EDT

Eli Lilly jumps into a $473M hunt with Sigilon for the Holy Grail in diabetes cell therapies

John Carroll

Editor & Founder

Stem cell therapies have gone through every stage of the long and painful hype cycle for emerging drug technologies: Starting with wildly inflated early expectations …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Eli Lilly jumps into a $473M hunt with Sigilon for the Holy Grail in diabetes cell therapies

John Carroll

Editor & Founder

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Deputy FDA chief mulls shaking up PDUFA reauthorization structure

Updated: Novo Nordisk CEO to step down amid stock decline, timeline for successor unknown

The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease

Lower attendance at cell and gene therapy conference mirrors challenged industry

FDA poses efficacy, safety questions over four cancer drugs ahead of two-day adcomm

'Go ahead and do it': Top RFK Jr. deputy dares drugmakers that might pull manufacturing over new price pressure

Eli Lil­ly jumps in­to a $473M hunt with Sig­ilon for the Holy Grail in di­a­betes cell ther­a­pies

Editor & Founder

Sign up to read this article for free.

more like this

ImmunityBio, Inc.

Remote

Eli Lilly jumps into a $473M hunt with Sigilon for the Holy Grail in diabetes cell therapies